• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Christel Bories fired by Ipsen’s board over strategy disagreement

Christel Bories fired by Ipsen’s board over strategy disagreement

February 23, 2016
CenterWatch Staff

Christel Bories, deputy CEO, has left Ipsen. Since her arrival in February 2013, Christel Bories has made a significant contribution to the operational transformation and improved results of Ipsen. Recently, the board of directors and Christel Bories have noted disagreements over the group's strategy. In accordance with the Afep-Medef corporate governance code, the board of directors has decided to grant the contractually agreed severance package to Christel Bories.

The board of directors of Ipsen, following its meeting on Feb. 15, has decided to adapt its corporate governance by separating the functions of chairman and chief executive officer (CEO), under the conditions laid down in the company's bylaws and after consulting the Nominations & Governance Committee.

Ipsen has initiated the process to recruit its future CEO with the goal of completing that process within the coming months. Marc de Garidel, Chairman and CEO of Ipsen, will become non-executive chairman upon the arrival of the new CEO and will continue to share with the board of directors his deep understanding of the sector.

Marc de Garidel, chairman and CEO of Ipsen, said, "The evolution in the corporate governance of Ipsen marks an important milestone in the Group's transformation. Underpinned by its independence and the support of its majority shareholder, the Group is confident in the outlook for its future. This evolution meets the need for our Group to accelerate its international development in an increasingly complex environment. The separation of functions will enable the CEO to concentrate on the business strategy, the pursuit of our transformation, and operations, while, as non-executive chairman, I will be able to focus fully on leading and animating the board of directors. Finally, I would like to extend my thanks to Christel Bories for her significant contribution as deputy CEO to the operational transformation, as well as to the teams who are fully mobilized."

Ipsen is a global specialty-driven biotechnological group with total sales exceeding €1.2 billion in 2014. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in 30 countries.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing